E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)

About this episode

This episode discusses a study on the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis, revealing significant findings.

Covering a very interesting study this week, which investiaged the PDE4B inhibitor nerandomilast for patients with progressive pulmonary fibrosis (specifically including 325 patients with autoimmune ILD). Would have been yet another ho hum trial if not for the big reveal... have a listen to find out! Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2503643

People in this episode

Host: Michael Putman

Topics covered

• autoimmune diseases
• pulmonary fibrosis
• PDE4B inhibitors
• clinical trials
• rheumatology

Keywords

• nerandomilast
• autoimmune ILD
• pulmonary fibrosis
• clinical trial
• PDE4B inhibitor

Mentioned in this episode

Organizations: NEJM

Products: nerandomilast

Places: autoimmune ILD

More episodes of The Evidence Based Rheumatology Podcast

• E135: IL17 and a GLP1? · April 30, 2026 · 11 min
• E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
• E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
• E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
• E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
• E130: Telitacicept for SLE · December 22, 2025 · 13 min